Carnosine Fatigue Randomized Trial: What the Evidence Says

Quick Answer

Carnosine Fatigue Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• L-carnosine (β-alanyl-L-histidine) is a naturally occurring bioactive dipeptide composed of β-alanine and L-histidine, predominantly found in tissues with high metabolic demands such as skeletal muscle and the central nervous system. [Hsiao Yung-Fang (2026); evidence level 1]
• Age-associated declines in muscle carnosine content have been associated with reduced exercise capacity and increased fatigue, whereas reductions in brain carnosine levels have been linked to oxidative damage, protein aggregation, and cognitive impairment in neurodegenerative conditions or aging. [Hsiao Yung-Fang (2026); evidence level 1]
• Carnosine (β-alanine-L-histidine) and its biochemically modified derivatives comprise a family of histidyl-containing dipeptides found in abundance in highly metabolic tissues (skeletal muscle, heart, brain) of all species. [O'Toole Timothy E. (2026); evidence level 2]
• In part due to such diverse roles, both clinical and animal studies have found that increasing carnosine levels can protect from ischemic injury, neurodegenerative disease, toxic outcomes of air pollution exposure, and promote wound healing, glucose handling and cognitive function. [O'Toole Timothy E. (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For carnosine fatigue randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Hsiao Yung-Fang (2026). The Effects of Carnosine on Cognitive Function and Mental Health—A Systematic Review and Meta-Analysis. DOI: 10.3390/nu18091385. PMCID: PMC13165363. PMID: 42123986. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13165363/
• O'Toole Timothy E. (2026). Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial. DOI: 10.1080/15502783.2026.2679716. PMCID: PMC13276806. PMID: 42308284. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13276806/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.